Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline

American Journal of Cardiology

Volumn 106, Issue 9, 2010, Pages 1307-1312

  Kajimoto, Katsuya ^a   Imai, Taku ^a   Minami, Yuichiro ^a   Kasanuki, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIBENZOLINE; DISOPYRAMIDE; PILSICAINIDE; PROPRANOLOL; VERAPAMIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART LEFT VENTRICLE PRESSURE; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHY, HYPERTROPHIC; DISOPYRAMIDE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; IMIDAZOLES; LIDOCAINE; LINEAR MODELS; MALE; MIDDLE AGED; PROPRANOLOL; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR PRESSURE; VERAPAMIL;

EID: 77958518671     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.06.059     Document Type: Article

References (28)

1. C. Pollick Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide N Engl J Med 307 1982 997 999
2. C. Pollick, B.P. Kimball, M. Hendreson, and E.D. Wigle Disopyramide in hypertrophic cardiomyopathy: hemodynamic assessment after intravenous administration Am J Cardiol 62 1988 1085 1088
3. B.P. Kimball, S. Bui, and E.D. Wigle Acute doseresponse effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy Am Heart J 125 1993 1691 1697
4. M.D. Flamm, D.C. Harrison, and E.W. Hancock Muscular subaortic stenosis: prevention of outflow obstruction with propranolol Circulation 38 1968 846 858
5. D.S. Thompson, N. Naqvi, S.M. Juul, R.H. Swanton, D.J. Coltart, B.S. Jenkins, and M.M. Webb-Peploe Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy Br Heart J 44 1980 488 498
6. D.R. Rosing, K.M. Kent, J.S. Borer, S.F. Seides, B.J. Maron, and S.E. Epstein Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy I. Hemodynamic effects Circulation 60 1979 1201 1207
7. S.E. Epstein, and D.R. Rosing Verapamil; its potential for causing serious complications in patients with hypertrophic cardiomyopathy Circulation 64 1981 437 441
8. D.M. Anderson, G.L. Raff, T.A. Ports, B.H. Brundage, W.W. Parmley, and K. Chatterjee Hypertrophic obstructive cardiomyopathy: effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function Br Heart J 51 1984 523 529
9. T. Shinozaki, S. Satoh, M. Miura, K. Iwabuchi, M. Takeuchi, S. Suzuki, S. Baba, H. Katoh, M. Funakoshi, M. Keitoku, J. Watanabe, N. Ishide, and K. Shirato The rise time of the monophasic action potential: a new index of local use-dependent conductivity by sodium channel blockers in human myocardium Jpn Circ J 61 1997 979 987
10. I. Kodama, S. Ogawa, H. Inoue, H. Kasanuki, T. Kato, H. Mitamura, M. Hiraoka, and T. Sugimoto Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit The Guideline Committee for Clinical Use of Antiarrhythmic Drugs in Japan Jpn Circ J 63 1999 1 12
11. M. Hamada, Y. Shigematsu, S. Ikeda, Y. Hara, H. Okayama, T. Ochi, and K. Hiwada Class 1a antiarrhythmic drug cibenziline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy Circulation 96 1997 1520 1524
12. Y. Minami, K. Kajimoto, M. Kawana, N. Hagiwara, and M.V. Sherrid Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy Int J Cardiol 141 2010 195 197
13. S. Haruki, Y. Minami, K. Kajimoto, B. Yashiro, T. Suzuki, M. Kawana, and N. Hagiwara Possible acute and chronic synergic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy: a case report Eur J Heart Fail 12 2010 94 97
14. M. Hamada, J. Aono, S. Ikeda, K. Watanabe, S. Inaba, J. Suzuki, T. Ohtsuka, and Y. Shigematsu Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy Circ J 71 2007 1540 1544
15. D. Horiuchi, A. Iwasa, K. Sasaki, S. Owada, M. Kimura, S. Sasaki, and K. Okumura Effect of pilsicainide on dominant frequency in the right and left atria and pulmonary veins during atrial fibrillation: association with its atrial fibrillation terminating effect Eur J Pharmacol 608 2009 54 61
16. M.V. Sherrid, I. Barac, W.J. McKenna, O.M. Elliot, S. Dickie, L. Chojnowska, S. Casey, and B.J. Maron Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy J Am Coll Cardiol 45 2005 1251 1258
17. M.S. Maron, I. Olivotto, S. Betocchi, S.A. Casey, J.R. Lesser, M.A. Losi, F. Cecchi, and B.J. Maron Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy N Engl J Med 348 2003 295 303 (Pubitemid 36119984)
18. B.J. Maron, W.J. McKenna, G.K. Danielson, L.J. Kappenberger, H.J. Kuhn, C.E. Seidman, P.M. Shah, W.H. Spencer III, P. Spirito, F.J. ten Cate, E.D. Wigle Task Force on Clinical Expert Consensus Documents American College of Cardiology Committee for Practice Guidelines European Society of Cardiology American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J Am Coll Cardiol 42 2003 1687 1713 (Pubitemid 37383745)
19. T. Tokudome, K. Mizushige, T. Ueda, S. Sakamoto, and H. Matsuo Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolola case report Angiology 50 1999 331 335
20. 2+ exchange system is related to the antiarrhythmic action of disopyramide Gen Pharmacol 20 1989 105 109
21. M. Holck, and W. Osterrieder Inhibition of the myocardial Ca2+ inward current by the class 1 antiarrhythmic agent, cibenzoline Br J Pharmacol 87 1986 705 711
22. M. Sherrid, E. Delia, and E. Dwyer Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy Am J Cardiol 62 1988 1085 1088
23. M.V. Sherrid, G. Pearle, and D.Z. Gunsburg Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy Circulation 97 1998 41 47
24. M.V. Sherrid Pathophysiology and treatment of hypertrophic cardiomyopathy Prog Cardiovasc Dis 49 2006 123 151
25. M. Hongo, M. Hongo, T. Nakatsuka, H. Takenaka, M. Tanaka, N. Watanabe, Y. Yazaki, and M. Sekiguchi Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy Cardiology 87 1996 6 11
26. M.V. Sherrid, D.Z. Gunsburg, S. Moldenhauer, and G. Pearle Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy J Am Coll Cardiol 36 2000 1344 1354
27. H. Matsubara, S. Nakatani, S. Nagata, F. Ishikura, Y. Katagiri, T. Ohe, and K. Kunio Miyatake Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy J Am Coll Cardiol 26 1995 768 775
28. B.J. Maron Hypertrophic cardiomyopathy: A systematic review JAMA 287 2002 1308 1320